Adult Dosing
Treatment of patients with HIV-1 infection (in combination with other antiretrovirals)
Viramune
- 200 mg PO qd for 14 days followed by 200 mg PO q12 hrs
Note: Any patient who experiences rash during the 14 day lead-in period should not have their dose increased until the rash has resolved. The lead-in dosing should not be continued longer than 28 days (at which point an alternative drug regimen should be sought)
Viramune XR
- For patients not taking immediate-release
- 200 mg immediate-release PO qd x 14 days followed by one 400 mg extended release PO qd
- Conversion from immediate-release to extended release
- Patients on 200 mg immediate-release PO bid may convert to 400 mg extended release PO qd without restarting
Notes:
- Any patient who experiences rash during the 14 day lead-in period should not have their dose increased until the rash has resolved. The lead-in dosing should not be continued longer than 28 days (at which point an alternative drug regimen should be sought)
- Do not cut, crush, or chew the tablet
Pediatric Dosing
- Safety and efficacy of extended release have not been established in pediatric patients
Treatment of patients with HIV-1 infection (in combination with other antiretrovirals)
16 yrs
- 200 mg PO qd for 14 days followed by 200 mg PO q12 hrs
>15 day
- 150 mg/m2/dose PO qd for 14 days followed by 150 mg/m2/dose PO bid
- MAX: 400 mg PO qd
Note:
- Any patient who experiences rash during the 14 day lead-in period should not have their dose increased until the rash has resolved. The lead-in dosing should not be continued longer than 28 days (at which point an alternative drug regimen should be sought)
[Outline]
See Supplemental Patient Information
- Nevirapine produces severe, life-threatening, fatal hepatotoxicity, cholestatic hepatitis and hepatic failure
- Development of prodromal signs or symptoms of fatigue, malaise, anorexia, nausea, jaundice, liver tenderness or hepatomegaly, with or without initially abnormal serum transaminase levels occurred after therapy
- Prolonged partial thromboplast time, rhabdomyolysis, hepatic encephalopathy has been reported after nevirapine use
- If rash develop in first 18 weeks of treatment transaminase levels should be checked immediately [US Black Box warning]
- Contraindicated in occupational and non-occupational post-exposure prophylaxis [US Black Box warning]
- Monitor patient in hepatic fibrosis or cirrhosis for evidence of drug-induced toxicity
- Monitor patient to detect potentially life-threatening hepatotoxicity or skin reactions while on therapy [US Black Box warning]
- Toxic epidermal necrolysis, organ dysfunction Stevens-Johnson syndrome have occurred on therapy [US Black Box warning]
Cautions: Use cautiously in
- Hepatic impairment
- Renal impairment
Supplemental Patient Information
- Advice patient about sever liver disease , skin reaction, caused by therapy may lead to death
- Advice patient to discontinue the treatment and examine medical evaluation if signs or symptoms of liver disease or severe skin reactions develop
- Alert patient, about increase transaminases at the start of therapy can cause greater risk of symptomatic events and asymptomatic increases in AST or ALT
- Advice mothers not to breastfeed if they are receiving therapy
Pregnancy Category:B
Breastfeeding: Unsafe, women with HIV infection should not breastfeed
Pricing data from www.DrugStore.com in U.S.A.
- Viramune 200 MG TABS [Bottle] (BOEHRINGER INGELHEIM)
60 mg = $606.99
180 mg = $1781.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
Drug Name: Viramune 200 MG Oral Tablet
Pill Image:
[
See full size image]
Ingredient(s): Nevirapine
Imprint: 54;193
Color(s): White
Shape: Oval
Size (mm): 19.00
Score: 2
Inactive Ingredient(s): cellulose, microcrystalline / lactose monohydrate / povidone / sodium starch glycolate type a potato / silicon dioxide / magnesium stearate
Drug Label Author:
Boehringer Ingelheim Pharmaceuticals Inc.
DEA Schedule:
Non-Scheduled
Drug Name: Viramune 200 MG Oral Tablet
Ingredient(s): Nevirapine
Imprint: 54;193
Color(s): White
Shape: Oval
Size (mm): 19.00
Score: 2
Inactive Ingredient(s): cellulose, microcrystalline / lactose monohydrate / povidone / sodium starch glycolate type a potato / silicon dioxide / magnesium stearate
Drug Label Author:
State of Florida DOH Central Pharmacy
DEA Schedule:
Non-Scheduled
